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Andreae and colleagues (2016) argue in defense of research involving the use of 
controlled substances for pain and other symptom control in HIVC patients 
by raising and defusing selected ethical and legal concerns about this research. 
While we do not dispute the importance of the research, we are concerned that 
their discussion construes the research and concomitant issues it raises too 
narrowly, particularly with respect to data use and confidentiality. In this brief 
comment, we note and briefly explore five additional issues about data collection 
and use with HIVC populations that, we believe, are critical to building a case 
for research with HIVC patients: data availability, data protection, risks of 
stigmatizing inferences about individuals, potential mismatches between  
research  participants  and research beneficiaries, and standards for 
interventional versus non-interventional research. We begin with two 
background observations, about the HIVC population and the nature of the 
research examined by Andreae and colleagues. 
 
The demographics of the HIVC population pose issues of justice. It is well 
known in the United States that African-Americans are the racial group most 
affected by HIV. According to recent Centers for Disease Control and 
Prevention (CDC) statistics 
(http://www.cdc.gov/hiv/group/racialethnic/africanamericans), African- 
Americans account for an estimated 44% of new HIV infections although they 
are only 12% of the population; the rate of new infections among African 
American males in 2010 was 7 times that of white males and twice that of 
Latino males. For African-American women, rates of new infections are 20 
times that of whites and 5 times those of Latinos. Estimates are that one in 
16 African-American men and 1 in 32 African-American women will be 
diagnosed with HIV at some point during their lives. Lower percentages of 
African Americans are linked to care, remain in care, receive appropriate 
prescriptions of antiretroviral therapy, and achieve viral suppression. These 
factors, together with the increased prevalence of other sexually transmitted 
diseases (STDs), unawareness of HIV status, and missed opportunities for 
treatment as prevention, contribute to increased burdens of disease in this 
population. Perhaps less well known in the United States are European data 
that HIV disproportionately affects migrants; in many West European 
countries more than half of new HIV diagnoses were in this population 
(European Centre for Disease Prevention and Control 2013). 
 
Second, the research model that Andreae and colleagues discuss is 
primarily interventional, most likely randomized controlled trials evaluating 
the safety and efficacy of controlled substances in selected patient 
populations. While such trials have been considered the gold standard, their 
prominence has recently been questioned. Issues include enrollment barriers, 
bias in study design or analysis, unwillingness to be randomized and other 
ethical or practical questions about randomization, whether study 
populations and conditions mirror real-world conditions such as adherence, 
endpoint selection, and inability to detect low-frequency events. All of these 
issues are likely to be present in research with HIVC populations, given the 
demographics just presented (West et al. 2008). Donnell and colleagues 
(2013), for example, recommend considering adherence in designing studies 
of pre-exposure prophylaxis for HIV. 
 
It may therefore be important to consider possibilities for types of research 
other than clinical trials of prohibited drugs or drugs of uncertain legal 
status. New statistical techniques of data analysis are enabling research using 
existing patient records that controls more effectively for selection bias 
(West et al. 2008). Data analyses in the 24 U.S. jurisdictions now allowing 
medical cannabis might provide evidence of safety and efficacy of cannabis 
use in HIV patients, to take one example. There are also possibilities of 
building on the extensive efforts to study methods for increasing willingness 
to be tested for HIV or to stay in HIV treatment. Results from such research 
might help build the case for federal support of the drug trials considered by 
Andreae and colleagues. Our suggestion here is that researchers should 
consider creative methods to avoid the more direct legal challenges of 
concern to Andreae and colleagues. The goal is to devise strategies that are 
within the legally available world to build the case for testing proscribed 
drugs for treating serious pain. But there are barriers and ethical concerns 
here as well, to which we now turn. 
 
1. Data availability.  In addition to the HIV population demographics that 
suggest that many are unaware of their status or not in care—so data 
may simply not be available—there may be special legal constraints on 
data involving treatment of patients using a controlled substance. The 
Substance Abuse and Mental Health Services Act (SAMHSA) part 2 
regulation imposes stringent consent requirements on disclosure of 
information about patients treated in substance abuse facilities 
receiving federal funds; it also imposes special requirements on 
research use of this data. These restrictions may make it more difficult 
to conduct research on HIV patients treated for substance abuse in 
these facilities. 
2. Data protection. As Andreae and colleagues indicate, the level of legal 
protection afforded by certificates of confidentiality is uncertain 
(Check et al. 2014). Deaths from abuse of opioids—both legal and 
illegal—are recognized as an important public health problem in the 
United States today (National Institute on Drug Abuse [NIDA] 2014) 
Drug use, drug diversion, and drug sales are an area of particular 
interest to police and prosecutors. Despite emphasis on the importance 
of education and public health efforts (NIDA 2014), efforts at 
investigation, mandated treatment, and even prosecution may be 
expected to intensify as well (Levulis 2015). Wolf et al. (2015) document 
the importance of clarifying confidentiality protection; enhanced 
protections are especially critical for doubly sensitive data such as 
information about patients who both are HIV positive and use controlled 
substances. 
3. Risks of stigmatizing inferences. Particularly when data sets are 
combined, novel and unanticipated inferences may appear. These 
inferences appear from a constellation of factors: that if a person has 
characteristics a-1 to a-n, the person also has characteristic a-nC1. To 
be sure, these inferences are likely to be probabilistic and with different 
levels of confidence. Nonetheless, if the inferred characteristic is 
troublesome, it may be stigmatizing. Importantly, these risks of stigma 
for individuals may arise even from research with de-identified data, 
without efforts to re-identify individuals in the data, and regardless of 
whether the individual about whom the inference was drawn was in the 
original data set. A poignant example from the history of HIV is 
inferences that were drawn about Haitians from data about original 
disease incidence (Capo' 2013). Researchers should recognize the 
possibility of these risks of stigma, the possibility that they might 
reduce willingness to participate, and take steps to communicate 
research in ways that mitigate these risks. 
4. Mismatches between participants and beneficiaries of research. When 
people permit data to be used in research, or when data about them are 
used without consent, they contribute to an overall public good. As a 
matter of minimal fairness it is reasonable to think that they should not 
be shut out from receiving the benefits of the good to which they 
contribute (Francis and Francis 2014). Given the demographic 
characteristics of the population with HIV—including the 
demographics of those who remain unaware of their status or who are 
not consistently in care—along with other data about racial and ethnic 
disparities in access to care more generally, such unfair mismatches are 
a genuine possibility with any HIV research. Where the research 
involves additional risks, such as research with HIV-positive people 
who also use controlled substances, attention to these fairness concerns 
is imperative. 
5. Interventional versus non-interventional research standards. Debates 
about whether the standards for protecting individuals in interventional 
research should differ from those appropriate to protecting individuals 
in non-interventional research are ongoing. The recent Common Rule 
NPRM, 80 Fed. Reg. 53933 (Sept. 8, 2015), proposes adding as a new 
category of exempt research secondary research use of identifiable 
private information originally collected as part of a non-research 
activity, where notice of such possible use was given and applicable 
privacy protections are in place including heightened protections for 
sensitive information. The uncertainty surrounding certificates of 
confidentiality suggests that risks may be attendant on this strategy, 
however. 
 
Building the case for research improving pain management in HIV patients is an urgent 
matter. Interventional research with controlled substances may need to be 
complemented with other research strategies, given existing legal risks and barriers. 
These complementary strategies— along with the research discussed by Andreae and 
col- leagues—require attention to the additional barriers we have explored in this 
comment. Ethical questions about this research must not be framed primarily as a binary 
choice between liberty and the need to solve a critical social problem. Considerations of 
justice must be at the fore, most notably risks to participants such as individuals newly 
infected with HIV who are among the most vulnerable of populations in the United 
States, in Europe, and else- where. Addressing these considerations of justice requires 
longer term strategies such a research on pain control in less vulnerable populations, 
non-interventional research, or other research methodologies that although not gold 
standard may still produce findings of value. Even partial or imperfect results may help 
build the case for reforming public policies that govern experimentation with con- 
trolled substances. There is value in the adoption of a risk- averse approach to research 
on controlled substances with HIV-infected patients so that these doubly vulnerable 
patients are not placed in legal harm’s way. 
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